老年小肠淋巴管扩张症合并药物性肝损伤1例报告

孔晓露; 邵雪; 李东复

doi:10.3969/j.issn.1001-5256.2019.08.030

老年小肠淋巴管扩张症合并药物性肝损伤1例报告

DOI: 10.3969/j.issn.1001-5256.2019.08.030

吉林大学第二医院肝胆胰内科

详细信息

中图分类号: R575;R574.5
计量
- 文章访问数: 990
- HTML全文浏览量: 9
- PDF下载量: 189
- 被引次数: 0
出版历程
- 出版日期: 2019-08-20

Senile intestinal lymphangiectasia with drug-induced liver injury: A case report

Department of Hepatology, The Second Hospital of Jilin University

摘要

摘要: <正>小肠淋巴管扩张症(intestinal lymphangiectasia,IL)是由于原发或继发性因素影响正常淋巴循环,导致淋巴管异常扩张而引起的蛋白丢失性胃肠病。淋巴液漏入肠腔或腹腔,淋巴液中含有的清蛋白、乳糜微粒、淋巴细胞等物质随之丢失,从而引起一系列临床症状,如水肿、低蛋白血症、多浆膜腔积液等[1]。现对本院诊治的IL病例进行介绍。1病例资料患者女性,70岁,因"发现双下肢水肿2年,加重4个月"于2018年11月29日入本院。患者2年前无明显诱因出现双下
- 淋巴管扩张,肠 /
- 药物性肝损伤 /
- 高脂血症
- lymphangiectasis, intestinal /
- drug-induced liver injury /
- hyperlipidemias

HTML全文

参考文献(14)

[1] SHEN HQ. Primary intestinal lymphangiectasia in children[J].J Appl Clin Pediatr, 2018, 33 (7) :490-495. (in Chinese) 沈惠青.儿童原发小肠淋巴管扩张症[J].中华实用儿科临床杂志, 2018, 33 (7) :490-495.

[2] LUO X, CUI HL, CHEN DF. Pentasa in treatment of intestinal lymphangiectasia:One case report[J]. Chin J Gastroenterol Hepatol, 2018, 27 (8) :954-956. (in Chinese) 罗茜, 崔红利, 陈东风.颇得斯安治疗小肠淋巴管扩张症1例报道[J].胃肠病学和肝病学杂志, 2018, 27 (8) :954-956.

[3] ALSHIKHO MJ, TALAS JM, NOURELDINE SI, et al. Intestinal lymphangiectasia:Insights on management and literature review[J]. Am J Case Rep, 2016, 17:512-522.

[4] WANG X, JIN H, WU W. Primary intestinal lymphangiectasia manifested as unusual edemas and effusions:A case report[J]. Medicine (Baltimore) , 2016, 95 (10) :e2849.

[5] LI YM, ZHANG BL. Current research status of intestinal lymphangiectasia[J]. J Diagn Concepts Pract, 2008, 7 (1) :9-11. (in Chinese) 厉有名, 张冰凌.小肠淋巴管扩张症的研究现状[J].诊断学理论与实践, 2008, 7 (1) :9-11.

[6] YE S, ZHAN X. Research advances in primary intestinal lymphangiectasia[J/CD]. Chin J Clinicians:Electronic Edition, 2016, 10 (11) :1613-1616. (in Chinese) 叶珊, 詹学.原发性小肠淋巴管扩张症的研究进展[J/CD].中华临床医师杂志:电子版, 2016, 10 (11) :1613-1616.

[7] FILIK L, OGUZ P, KOKSAL A, et al. A case with intestinal lymphangiectasia successfully treated with slow-release octreotide[J]. Dig Liver Dis, 2004, 36 (10) :687-690.

[8] MACLEAN JE, COHEN E, WEINSTEIN M, et al. Primary intestinal and thoracic lymphangiectasia:A response to antiplasmin therapy[J]. Pediatrics, 2002, 109 (6) :1177-1180.

[9] OZEKI M, HORI T, KANDA K, et al. Everolimus for primary intestinal lymphangiectasia with protein-losing enteropathy[J]. Pediatrics, 2016, 137 (3) :e20152562.

[10] DONG J, XIN JF, HUO M, et al. Direct lymphangiography with sequential CT lymphangiography in secondary intestinal lymphangiectasia:A retrospective study[J]. J Clin Radiol, 2018, 37 (3) :419-423. (in Chinese) 董健, 信建峰, 霍萌, 等.直接淋巴管造影与CT淋巴管成像在继发性小肠淋巴管扩张症的回顾性研究[J].临床放射学杂志, 2018, 37 (3) :419-423.

[11] ZHANG Y, HAN DD, ZHAO X, et al. Long-term application of atorvastatin calcium caused liver injury:One case report[J]. Chin J Pharmacoepidemiol, 2016, 25 (8) :526-527. (in Chinese) 张莹, 韩东冬, 赵昕, 等.长期应用阿托伐他汀钙致肝损伤1例[J].药物流行病学杂志, 2016, 25 (8) :526-527.

[12] ZENG HQ, ZHANG Q, PENG WX. Mechanism of atorvastatin-induced liver injury[J]. ADRJ, 2012, 14 (4) :232-236. (in Chinese) 曾含清, 张琼, 彭文兴.阿托伐他汀致肝损伤的机制[J].药物不良反应杂志, 2012, 14 (4) :232-236.

[13] LIU MH, CHEN CZ. Cost analysis of liver injury caused by atorvastatin in 11 patients[J]. Strait Pharm J, 2018, 30 (2) :265-268. (in Chinese) 刘敏惠, 陈崇泽.阿托伐他汀致11例患者肝损伤及费用分析[J].海峡药学, 2018, 30 (2) :265-268.

[14] PENG JL, MA GW, YU ML, et al. Experimenrtal study of liver injury caused by lovastatin combined with isoniazid, rifampicin and pyrazinamide in rats[J]. Anhui Med Pharm J, 2017, 21 (12) :2157-2163. (in Chinese) 彭江丽, 马国伟, 喻明丽, 等.洛伐他汀联合异烟肼、利福平、吡嗪酰胺致大鼠肝损伤的实验研究[J].安徽医药, 2017, 21 (12) :2157-2163.

施引文献

资源附件(0)

访问统计